Search Results

There are 8151870 results for: content related to: Parkinson's Disease

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  3. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  4. Levodopa

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S23–S37,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5558

  5. You have free access to this content
    Abstracts of The Movement Disorder Society's Eleventh International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 22, Issue S16, 2007, Pages: S1–S325,

    Version of Record online : 24 APR 2007, DOI: 10.1002/mds.21535

  6. Poster session 2, Abstracts 345–694

    Movement Disorders

    Volume 19, Issue S9, 2004, Pages: S129–S244,

    Version of Record online : 10 MAY 2004, DOI: 10.1002/mds.20176

  7. Dyskinesia Induced by Levodopa and Dopamine Agonists in Patients with Parkinson's Disease

    Drug Induced Movement Disorders, Second Edition

    John G. Nutt, Matthew A. Brodsky, Pages: 313–350, 2008

    Published Online : 14 JAN 2008, DOI: 10.1002/9780470753217.ch13

  8. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Version of Record online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  9. Poster Sessions: Clinical Science

    Movement Disorders

    Volume 21, Issue S13, January 2006, Pages: S81–S134,

    Version of Record online : 19 JAN 2006, DOI: 10.1002/mds.20871

  10. Poster Session 3

    Movement Disorders

    Volume 21, Issue S15, September 2006, Pages: S517–S613,

    Version of Record online : 20 SEP 2006, DOI: 10.1002/mds.21248

  11. Poster session 1: A. Basic science, genetics, neuropharmacology, Parkinson's Disease

    Movement Disorders

    Volume 17, Issue S5, November 2002, Pages: S17–S64,

    Version of Record online : 21 OCT 2002, DOI: 10.1002/mds.10349

  12. Poster Session 2

    Movement Disorders

    Volume 21, Issue S15, September 2006, Pages: S425–S516,

    Version of Record online : 20 SEP 2006, DOI: 10.1002/mds.21247

  13. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

    Clinical Pharmacology & Therapeutics

    Volume 67, Issue 6, June 2000, Pages: 610–620, Karin Jorga, Ludger Banken, Bärbel Fotteler, Paul Snell and Jean-Louis Steimer

    Version of Record online : 15 JUN 2000, DOI: 10.1067/mcp.2000.106795

  14. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

    Annals of Neurology

    Volume 43, Issue 5, May 1998, Pages: 561–575, Dr M. Gustavo Murer, Gustavo Dziewczapolski, Liliana B. Menalled, M. Carmen García, Yves Agid, Oscar Gershanik and Rita Raisman-Vozari

    Version of Record online : 8 OCT 2004, DOI: 10.1002/ana.410430504

  15. You have free access to this content
    Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease

    Neurology and Clinical Neuroscience

    Volume 3, Issue 2, March 2015, Pages: 68–73, Hirotaka Iwaki, Noriko Nishikawa, Masahiro Nagai, Tomoaki Tsujii, Hayato Yabe, Madoka Kubo, Ichiro Ieiri and Masahiro Nomoto

    Version of Record online : 8 DEC 2014, DOI: 10.1111/ncn3.152

  16. You have free access to this content
    THE ABSORPTION AND METABOLISM OF A STANDARD ORAL DOSE OF LEVODOPA IN PATIENTS WITH PARKINSONISM

    British Journal of Clinical Pharmacology

    Volume 1, Issue 5, October 1974, Pages: 417–424, S. BERGMANN, G. CURZON, J. FRIEDEL, R.B. GODWIN-AUSTEN, C.D. MARSDEN and J.D. PARKES

    Version of Record online : 26 JUL 2012, DOI: 10.1111/j.1365-2125.1974.tb00280.x

  17. Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients

    Journal of Pharmaceutical Sciences

    Volume 69, Issue 12, December 1980, Pages: 1374–1378, Kunihiro Sasahara, Takashi Nitanai, Taeko Habara, Tadashi Morioka and Eiichi Nakajima

    Version of Record online : 22 SEP 2006, DOI: 10.1002/jps.2600691205

  18. Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?

    Annals of Neurology

    Volume 47, Issue 5, May 2000, Pages: 655–658, Boulos-Paul Bejjani, Isabelle Arnulf, Sophie Demeret, Philippe Damier, Anne-Marie Bonnet, Jean-Luc Houeto and Yves Agid

    Version of Record online : 3 MAY 2001, DOI: 10.1002/1531-8249(200005)47:5<655::AID-ANA16>3.0.CO;2-#

  19. You have full text access to this OnlineOpen article
    Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 94–105, Ahmed A. Othman and Sandeep Dutta

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12324

  20. Pharmacotherapy for Advanced Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 1P2, January 2000, Pages: 8S–16S, Mark Stacy

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.20.2.8S.34630